Skip to main content

AXGN AxoGen, Inc.

Healthcare

50.89 USD 1D +0.25 +0.49% Close 11/10
Since 2024-12-10 +241.2%

Close 11/10

Open
49.70
High
51.10
Low
49.23
Prev close
50.64
Volume
1.04M
Amplitude
3.69%
P/B
6.1
Revenue YoY (TTM)
+24.3%
52W 23.00 52.91
FinLab Studio

From AxoGen, Inc. to every stock like it

AI finds several complementary traits of AxoGen, Inc. across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like AxoGen, Inc.

Is AxoGen, Inc. a buy? Fundamentals and valuation first

As of 2026-11-09

Growth: Strong, Momentum: Strong; Valuation: Pricey.

Valuation Pricey Free-cash-flow yield is Good, but Price / book is Expensive.
TTM P/E -77.9 N/A
Price / book 6.1 86th percentile · Expensive
Free-cash-flow yield (%) 0.5 50th percentile · Good
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Neutral FCF margin, TTM is Good, but Operating margin, TTM is Average.
ROE, TTM (%) -6.4 33th percentile · Average
Operating margin, TTM (%) -5.2 30th percentile · Average
FCF margin, TTM (%) 6.1 54th percentile · Good
Quality Factor Investing: A US Quality Value Backtest
Growth Strong Diluted EPS growth, TTM YoY is Top; Revenue growth, TTM YoY is Good.
Revenue growth, TTM YoY (%) 24.3 77th percentile · Good
Diluted EPS growth, TTM YoY (%) 1,229.2 97th percentile · Top
Momentum Strong 240-day return is Top; 60-day return is Good.
60-day return (%) 3.9 79th percentile · Good
240-day return (%) 78.4 94th percentile · Top
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Neutral 20-day dollar volume is Top, but 60-day annualized volatility is Average.
20-day dollar volume 81,751,645.0 85th percentile · Top
60-day annualized volatility (%) 81.0 74th percentile · Average
Factor Investing Explained: 10 Classic Factors in US Stocks

AxoGen, Inc. (AXGN) today

2 quant signals active · As of 2026-11-09

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

AxoGen, Inc. (AXGN) peers and tracking

Watchlist

This page refreshes daily after the close. Add AxoGen, Inc. to your watchlist to track signal changes on your next visit.

AxoGen, Inc. (AXGN) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Filed revenue acceleration

Active · now 24.3%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

13 historical occurrences (since 2021-05-06)

Average forward return after Filed revenue acceleration

20-day: Win 50.0%, Sample 12, Median -2.4%, Excess +0.5%, Beat mkt rate 41.7%

60-day: Win 41.7%, Sample 12, Median -6.8%, Excess -1.1%, Beat mkt rate 33.3%

120-day: Win 63.6%, Sample 11, Median +40.8%, Excess +11.4%, Beat mkt rate 63.6%

120 days after: historical avg +18.8%

20-day +2.4%
60-day +3.3%
120-day +18.8%
20-day
60-day
120-day
Win
50.0%
41.7%
63.6%
Sample
12
12
11
Median
-2.4%
-6.8%
+40.8%
Excess
+0.5%
-1.1%
+11.4%
Beat mkt rate
41.7%
33.3%
63.6%

Over 11 occurrences, 120-day forward avg gained 18.8%, beat the market by 11.4 pts; win rate 63.6%.

EPS surprise beat

Active · now 59.9%

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest
33 historical occurrences (since 2015-05-05)

Average forward return after EPS surprise beat

20-day: Win 58.6%, Sample 29, Median +1.3%, Excess +3.4%, Beat mkt rate 48.3%

60-day: Win 69.0%, Sample 29, Median +15.0%, Excess +8.1%, Beat mkt rate 62.1%

120-day: Win 62.1%, Sample 29, Median +29.4%, Excess +15.3%, Beat mkt rate 65.5%

120 days after: historical avg +23.1%

20-day +5.5%
60-day +12.4%
120-day +23.1%
20-day
60-day
120-day
Win
58.6%
69.0%
62.1%
Sample
29
29
29
Median
+1.3%
+15.0%
+29.4%
Excess
+3.4%
+8.1%
+15.3%
Beat mkt rate
48.3%
62.1%
65.5%

Over 29 occurrences, 120-day forward avg gained 23.1%, beat the market by 15.3 pts; win rate 62.1%.

More history: Market-wide momentum baseline, Signals not active now

Market-wide momentum baseline

Across 100,435 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.41%, a 58.4% positive-return rate, and +3.07 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

22 times historically; 60-day forward avg +8.0%, win rate 63.6%, beating the market by +6.1 pts on average.

Top-quintile 6-month momentum

Pending

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest

22 times historically; 60-day forward avg +10.5%, win rate 66.7%, beating the market by +6.1 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.